Download PDF

This Pfizer-sponsored study used de-identified data derived from the Flatiron Health Analytic Database in a retrospective observational study to demonstrate palbociclib (PAL) combined with an aromatase inhibitor (AI) is an effective first-line therapy for treating metastatic breast cancer.

 

Hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic/advanced breast cancer (HR+/HER2– MBC) is the most common form of metastatic breast cancer. HR+/HER2– MBC often shows poor clinical outcomes due to multiple organ involvement and highlights the need for better treatments. Given its poor prognosis, analysis of the efficacy of already approved treatments can help the clinical decision-making in patients with advanced breast cancer.

 



Flatiron is an oncology platform licensed to large oncology pharmaceutical companies that aggregates patient data from EHRs, lab and medical claims and matches it with patient trial data. The data originates from 2.4 million actively treated cancer patients in the U.S., which can be used to provide real-world evidence of patient outcomes in retrospective research. In the current study, real-world progression-free survival (rwPFS) and best tumor response (rwBTR) were assessed in 813 patients with HR+/HER2– MBC. The time from starting PAL+AI to death or disease progression was defined as rwPFS, whereas the treating clinician’s assessment of change in disease burden based on imaging was defined as rwBTR. 

 

About 86.5% of the patients started PAL at 125 mg/day, with 13.5% using lower doses. About 11% stopped use due to toxicity. PAL treatment at 125 mg/day was associated with improved outcomes compared to the lower doses. Both rwPFS and rwBTR rate improved in comparison to the lower doses (27.8 vs 18.6 months and (54.0% vs 40.4%, respectively). Thus these data show the benefit of the combined PAL+AI treatment at the starting dose of 125 mg/day in routine clinical practice to treat HR+/HER2– MBC.


For more Women's Health newsClick here 


Source:Clinical Breast Cancer

 

«« Telehealth Follow-up Compares Well to In-Person Care For Chronic Conditions


Connecting Healthcare Providers with Patients »»

References:

Patt D et al. (2022) Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clinical Breast Cancer.



breast cancer, breast screening, womens health care

Latest Articles

  • Pharmacist in the ICU

    Pharmacists play a crucial role in the ICU, where patients often require complex medication regimens, including multiple medications and intravenous therapies. The role of a critical care pharmacist is multifaceted and vital to ensuring optimal patient care in the critical care setting.   Cr

    READ MORE
  • Defining Medicines Optimisation in the Intensive Care Unit

      Complex polypharmacy and pathophysiology are common in the intensive care unit (ICU). Medicines optimisation is essential to deliver safe, effective, and individualised pharmacotherapy. This is ideally performed by a specialised ICU pharmacist.   Introduction Medicines ar

    READ MORE
  • Critical Care Pharmacists Save Lives

      The purpose of this review is to discuss the role of critical care pharmacists on the interprofessional healthcare team in the care of critically ill patients and explore current gaps in the provision of comprehensive medication management.   Introduction   “The patient’s

    READ MORE
Pfizer, metastatic breast cancer, Breast Cancer, Screening, Womens Health This Pfizer-sponsored study used de-identified data derived from the Flatiron Health Analytic Database in a retrospective observational study to demonstrate Palbociclib (PAL) combined with an aromatase inhibitor (AI) is an effective first-line therapy for